Berlin/Boston, March 20, 2014 ‒ Piramal Imaging today announced that the U.S. Food and Drug Administration (FDA) has approved Neuraceq™. This approval comes only four weeks after receiving marketing authorization for Neuraceq™ from the European Commission. Neuraceq™ is indicated for …

FDA Approves Piramal Imaging’s NeuraceqTM (florbetaben F18 injection) for PET Imaging of Beta-Amyloid Neuritic Plaques in the Brain Read More »

February 18, 2014   On behalf of the World Molecular Imaging Congress (WMIC) Scientific Program Committee, you are invited to submit an abstract for presentation or publication at the WMIC 2014, September 17 – 20 in Seoul, Korea. “This year’s …

Call for Abstracts: WMIC 2014 “Propelling Discoveries with Molecular Imaging” Read More »

November 05, 2013

The field of molecular imaging is grazed by two different animals—the workhorses, such as SPECT, PET and tried-and-true biomarkers like FDG, and the young, intrepid and unpredictable newcomers that have been given a name, taken around the track a couple times, but perhaps are still too fresh to be saddled with the responsibility of routine clinical use.

October 11, 2013

Molecular imaging has vast potential to improve healthcare in the coming years by allowing more directed, personalized therapy. But molecular imaging’s contribution may be limited until more imaging specialists are trained to interpret scans acquired with the new types of tracers being developed.

October 21, 2013

Molecular imaging holds the promise for improved patient management in medicine and surgery. To realize this goal, a thorough understanding of the instrumentation and diagnostic agents that comprise the field is necessary.